Skip to main content
SSO 2026 Annual Meeting Main banner

Wen-Ling Kuo, MD PhD (she/her/hers)

Chair of Breast Cancer Center
Chang Gung Memorial Hospital, Taipei, Taiwan (Republic of China)

CURRICULUM VITAE
Wen-Ling Kuo 郭玟伶 (Sylvie Kuo)

Personal Information
 Date of Birth: November 19, 1976
 Place of Birth: Taipei, Taiwan
 Citizenship: Taiwan
 Office Address: No. 5, Fu-Hsing St., Guishan Township, Taoyuan County 333, Taiwan
 Telephone: +886-3-3281200 ext. 3219
 Fax: +886-3-3285818
 Email: sylvie5285@gmail.com
 Languages: Mandarin, Holo, English, French

Education
 M.D., Department of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan (1994–2001)
 Ph.D., Graduate Institute of Clinical Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan (2007–2018)
 Visiting Scientist, Department of Molecular and Cellular Oncology, UT MD Anderson Cancer Center, Texas, US (2013–2016)

Professional Training
 Clerkship and Internship, Veteran General Hospital, Taipei (1999–2001)
 Resident Doctor, Department of Surgery, Chang Gung Memorial Hospital, Linko, Taiwan (2001–2006)
 Surgical Training Workshop, Intuitive Surgical Deutschland GmbH, Medizin im Grünen, Wendisch-Rietz, Germany (October 2021)

Current Appointments
 Associate Professor, Division of General Surgery and Breast Surgery, Department of Surgery, Chang Gung Medical Foundation, Linko and Taipei, Taiwan (July 2024–Present)
 Jointly Appointed Assistant Professor, School of Medicine, National Tsing Hua University / Chang Gung University (June 2022–Present)
 Director, Comprehensive Breast Cancer Center, Chang Gung Memorial Hospital Northern Medical Complex (January 2022–Present)
 Deputy Chair of International Affairs, Taiwan Breast Cancer Society (November 2024-Present)
 Executive Auditor of the Society of International Microsurgical Club (September 2025-Present)
 Member, Committee of Social Service, Taiwan Oncology Society (November 2020-Present)
 Member, Biobank Ethics Committee, Chang Gung Memorial Hospital, Linkou (May 2021–Present)
 Member, Tumor Committee, Chang Gung Memorial Hospital (February 2021–Present)
 Instructor Physician, Surgical Oncology Specialty Training Program (July 2012–Present)

Previous Appointments
 Member, Social Service Committee, Taiwan Oncology Society (November 2020–Present)
 Medical Export Reviewer, National Health Insurance, Taiwan (March 2020–Present)
 Assistant Professor & Attending Surgeon, Division of General Surgery and Breast Surgery, Department of Surgery, Chang Gung Medical Foundation, Linko and Taipei, Taiwan (July 2018–Present)
 Supervisor, Taiwan Oncoplastic Breast Surgery Society (August 2017–Present)
 Deputy Secretary General, Breast Cancer Society of Taiwan (2008–2012)
 Instructor & Attending Surgeon, Division of General Surgery and Breast Surgery, Department of Surgery, Chang Gung Medical Foundation, Linko and Taipei, Taiwan (August 2012–Present)
 Attending Surgeon, Division of General Surgery and Breast Surgery, Department of Surgery, Chang Gung Medical Foundation, Linko and Taipei, Taiwan (2007–Present)

Fields of Interest
Breast surgery, robot-assisted mastectomy, genetic testing consultation for breast cancer, cancer screening and diagnosis, adjuvant and neoadjuvant therapies, precision medicine, artificial intelligence applications in breast cancer care, and cancer immunology.

Awards and Honors
 Travel Award Winner, 15th International Symposium, Society of Chinese Bioscientists in America (2015)
 Premium Award for Oral Presentation in Breast Cancer, Annual Conference of Taiwan Surgical Association (2017)
 Poster Award, Global Breast Cancer Conference (GBCC) (2020)
 Best Paper Award, Taiwan Surgical Association (2023)

Licensure
 Medical Doctor, Taiwan, License No.: 033071
 Surgeon, Taiwan, License No.: 005433
 Digestive Surgery Specialist, Taiwan, No.: 1237
 Breast Specialist Physician, Taiwan, No.: 0530
 Breast Surgeon Specialist Physician, Taiwan, No.: 0530
 Surgical Oncologist Specialist Physician, Taiwan

Professional Affiliations
 Taiwan Surgical Association
 Breast Cancer Society of Taiwan (Deputy Secretary General, 2008–2012)
 Taiwan Surgical Society of Gastroenterology
 The Chinese Oncology Society
 Taiwan Oncoplastic Breast Surgery Society
 Society of International Surgical Club

Research Projects
1. Establishment of breast cancer and normal epithelial cell lines from Asian women. 2006-2008 CMRPG, PI
2. Characterization of breast cancer cell lines established from Taiwanese women. 2009~2010
CMRPG, PI
3. Stromal activation in the progression of high ErbB2/1433ζ DCIS to metastatic IBC. RO1CA112567, CO-PI
4. Accuracy of axillary sentinel lymph node biopsy in node-positive breast cancer converting to node-negative after neoadjuvant chemotherapy as detected by ultrasound. CORPG. PI
5. A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC). 2017/04/17~2018/04/16 XMRPG, CO-PI
6. A Phase III Randomized Study to investigate the efficacy and safety of Atezolizumab (anti-PD-L1 antibody) in combination with neoadjuvant Anthracycline/nab-paclitaxel-based chemotherapy compared with placebo and chemotherapy in patients with primary invasive triple-negative breast cancer. 2017/09/01~2018/02/28 XMRPG, CO-PI
7. MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. 2017/08/15~2018/08/14 XMRPG, CO-PI
8. Assessment of 14-3-3zeta related immunosuppressive markers of tumor-associated macrophages and tumor-infiltrating lymphocytes in triple-negative breast cancer. 2018/08/01~2019/07/31 NMRPG, PI
9. Retrospective analysis of clinicopathological features and treatment outcome of bilateral breast cancer patients. 2018/10/01~2019/09/30. CORPG, PI
10. Characterization of metabolic signature to predict HR+ HER2- metastatic breast cancer patients’ response to CDK4/6-based therapy. 2020/01/01~2020/12/31. CORPG
11. Patient-reported outcome measurement of da Vinci robot-assisted breast surgery. 2019/12/01~2020/11/30. CORPG, PI
12. Glycosylation of PKM2 controls metabolic adaptation and progression of breast cancer. 2017/09~2023/08 NMRPG, CO-PI
13. EPIK-B3: A Phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple-negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation. 2020/09/10~2021/09/30, XMRPG3K0681, CO-PI
14. A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer. 2019/04/30~2022/04/30, XMRPG3J0281~XMRPG3J0283, CO-PI
15. A Phase III, Randomized, Double-blind, Placebo Controlled Study of Adagloxad Simolenin (OBI 822)/OBI 821 Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients, defined as Residual Invasive Disease following Neoadjuvant Chemotherapy OR ≥ 4 Positive Axillary Nodes. 2019/08/28~2021/08/31, XMRPG3J0891 & XMRPG3J0892, CO-PI
16. A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756). 2019/02/21~2022/08/28, XMRPG3J0091~XMRPG3J0093, CO-PI
17. A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with HerceptinR as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer. 2019/07/04~2021/07/31, XMRPG3J0581 & XMRPG3J0582, CO-PI
18. A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC). 2017/05/31~2022/05/31, XMRPG3G0491~XMRPG3G0495, CO-PI
19. A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor-positive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study. 2019/05/14~2022/05/31, XMRPG3J0371, CO-PI
20. A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06). 2021/02/19~2022/02/28, XMRPG3L0381, CO-PI
21. SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. 2021/04/08~2022/04/30, XMRPG3L0781, CO-PI
22. A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07). 2021/05/10~2022/05/31, XMRPG3L0981, CO-PI
23. A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08). 2021/05/10~2022/05/31, XMRPG3L0971, CO-PI
24. A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. 2021/01/05~2022/01/31, XMRPG3L0061, CO-PI
25. PIK3CA Registry: A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer. 2021/02/04~20220/02/28, XMRPG3L0421, CO-PI
26. A PHASE II, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMPARED WITH PHYSICIAN'S CHOICE OF ENDOCRINE MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER. 2021/01/20~2022/01/31, XMRPG3L0141, CO-PI
27. A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER. 2019/12/10~2021/12/31, XMRPG3J1251 & XMRPG3J1252, CO-PI
28. MonarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer. 2017/09/14~2021/09/30, XMRPG3G0881~XMRPG3G0884, CO-PI
29. Complementary Treatment of PG2 to Improve Fatigue among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy. 2018/01/24~2021/12/31, XMRPG3H0141~XMRPG3H0144, CO-PI
30. A Phase 3 Asian study of sacituzumab govitecan (IMMU-132) versus treatment of the physician's choice (TPC) in subjects with hormonal receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2) metastatic breast cancer (MBC) who have failed at least 2 prior chemotherapy regimens. 2021/02/26~2022/02/28, XMRPG3L0431, CO-PI
31. Characterization of metabolic signature to predict HR+ HER2- metastatic breast cancer patients’ response to CDK4/6-based therapy. 2020/01/01~2021/06/30, CORPG1K0011, PI
32. Patient-reported outcome measurement of da Vinci robot-assisted breast surgery. 2019/12/01~2021/11/30, CORPG1J0041, PI
33. Time serial genomic alterations in triple-negative and luminal B breast cancer. 2020/02/01~2022/01/31, IRB: 202000141A3, PI
34. Development of breast cancer image automatic detection technology. 2020/01/01~2022/12/31, IRB: 201902289B0, PI
35. Whole exome and low-coverage whole genome sequencing analysis of germline variants in familial mutation risk-enriched breast cancer. 2021/09/01~2022/08/31, CRRPG1L0011, IRB:202002022A3, PI
36. Development of metabolic signatures to predict clinical outcome for early breast cancer. 2022/01/01~2023/12/31, CORPG1M0011, IRB: 202101304A3, PI
37. Metabolic mapping of breast cancer of different molecular subtypes. IRB: 202101746B0, PI
38. A pilot study of robot-assisted nipple-sparing mastectomy followed by immediate breast reconstruction using da Vinci SP ® single-port system, 2021/12/01~2022/11/30, CIRPG1M0011, IRB: 202101421A0, PI

Published Papers
1. Differential Expression of Claudin-4 Between Intestinal and Diffuse-type Gastric Cancer; Oncology Reports, 16: 720-734, 2006
Kuo WL, Lee LY, Wu CM, Wang CC, Yu JS, Liang Y, Lo CH, Huang KH, Hwang TL
2. MRI findings of cancers preoperatively diagnosed as pure DCIS at core needle biopsy
Acta Radiol. 2011 Dec 1;52(10):1064-8
Huang YT, Cheung YC, Lo YF, Ueng SH, Kuo WL, Chen SC
3. Favorable Outcome of Secondary Axillary Dissection in Breast Cancer Patients with Axillary Nodal Relapse, Annals of Surgical Oncology, 2012 Apr;19(4):1122-8
Shih-Che Shen, Chien-Hung Liao, Yung-Feng Lo, Hsiu-Pei Tsai, Wen-Ling Kuo, Chi-Chang Yu, Tzu-Chieh Chao, Miin-Fu Chen, Hsien-Kun Chang, Yung-Chang Lin, Wen-Chi Shen, Shir-Hwa Ueng, Li-Yu Lee, Swei Hsueh, Yi-Ting Huang, Shin-Cheh Chen
4. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J Gastrointest Surg. 2012 Feb;16(2):361-
Kuo WL, Yu MC, Lee JF, Tsai CN, Chen TC, Chen MF
5. The expression of cytokeratin 19 in lymph nodes was a poor prognostic factor for hepatocellular carcinoma after hepatic resection. World J Surg Oncol. 2013 Jun 12;11(1):136.
Lee CW, Kuo WL, Yu MC, Chen TC, Tsai CN, Lee WC, Chen MF.
6. Low re-excision rate for positive margins in patients treated with ultrasound-guided breast-conserving surgery. Breast. 2013 Oct;22(5):698-702.
Chi-Chang Yu, Kun-Chun Chiang, Wen-Lin Kuo, Shih-Che Shen, Yung-Feng Lo, Shin-Cheh Chen.
7. 14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. Cancer Cell. 2015 Feb 9;27(2):177-92.
Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ,
Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, Hung MC, Zhang JD, Yu D.
8. Establishment Of Two Basal-Like Breast Cancer Cell Lines with Extremely Low Tumorigenecity From Taiwanese Premenopausal Women. Human Cell 2018 Apr;31(2):154-166.
Wen-Ling Kuo, Shir-Hwa Ueng, Chun-Hsing Wu, Li-Yu Lee, Yun-Shien Lee, Ming-Chin Yu, Shin-Chen Chen, Chi-Chang Yu, Chi-Neu Tsai.
9. Nipple-sparing Mastectomy and Immediate Breast Reconstruction After Recurrence From Previous Breast Conservation Therapy. Ann Plast Surg. 2019 Jan;82(1S Suppl 1):S95-S102.
Lee CH, Cheng MH, Wu CW, Kuo WL, Yu CC, Huang JJ.
10. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomed J. 2019 Feb;42(1):66-74.
Chou HH, Kuo WL, Yu CC, Tsai HP, Shen SC, Chu CH, Yu MC, Lo YF, Dabora MA, Chang HK, Lin YC, Ueng SH, Chen SC.
11. BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling. J Gynecol Oncol. 2019 Oct 25.
Chao A, Lin YH, Yang LY, Wu RC, Chang WY, Chang PY, Chang SC, Lin CY, Huang HJ, Lin CT, Chou HH, Huang KG, Kuo WL, Chang TC, Lai CH.
12. Robot-assisted Mastectomy Followed by Immediate Autologous Microsurgical Free Flap Reconstruction: Techniques and Feasibility in Three Different Breast Cancer Surgical Scenarios. Clin Breast Cancer(Case Reports). Clin Breast Cancer. 2020 Feb;20(1):e1-e8.
Kuo WL*, Huang JJ*, Huang YT, Chueh LF, Lee JT, Tsai HP, Chen SC.
13. Prognostic study for isolated local recurrence operated with salvage excision in hormone-receptor-positive patients with invasive breast cancer after primary breast surgery. Biomed J. 2020 Feb;43(1):83-93.
Chi-Chang Yu, Wen-Lin Kuo, Shih-Che Shen, Hsu-Huan Chou, Yung-Feng Lo, Ming-Chin Yu, Shin-Cheh Chen
14. Consensus Statement on Robotic Mastectomy-Expert Panel From International Endoscopic and Robotic Breast Surgery Symposium (IERBS) 2019. Ann Surg. 2020 Jun;271(6):1005-1012.
Hung-Wen Lai, Antonio Toesca, Benjamin Sarfati, Hyung Seok Park, Gilles Houvenaeghel, Jesse C Selber, Fiona Tsui-Fen Cheng, Wen-Ling Kuo, Nickolas Peradze, Seung Yong Song, Chi Wei Mok
15. Adenoid Cystic Carcinoma of the Breast Detected with Contrast-Enhanced Spectral Mammography: A Case Report.
Current Medical Imaging. 2021;17(4):539-543.
Yun-Chung Cheung*, Shir-Hwa Ueng, Shu-Hang Ng, Wen-Lin Kuo
16. Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study. BMC Cancer. 2021 May ;21(1):522.
Jia-Ruei Yang, Wen-Ling Kuo, Chi-Chang Yu, Shin-Cheh Chen, Jung-Ju Huang
17. Breast Cancer Larger Than 2.5 cm with Tumor-Free Radioisotope-Hot Sentinel Nodes Has Higher Risk of Non-Hot Axillary Lymph Node Metastasis. Biomedical Journal 2022 Apr;45(2):396-405.
Yu-Ling Liu, Wen-Ling Kuo*, Yong-Feng Lo, Hsiou-Pei Tsai, Shih-Che Shen, Chi-Chang Yu, Shih-Huan Chou, Chia-Huei Chu, Shin-Cheh Chen
18. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer. Theranostics 2021; 11(16): 7779-7796.
Meng-Jen Wu, Chih-Jung Chen, Ting-Yu Lin, Ying-Yuan Liu, Lin-Lu Tseng, Mei-Ling Cheng, Chih-Pin Chuu, Huai-Kuang Tsai, Wen-Ling Kuo, Hsing-Jien Kung, Wen-Ching Wang
19. Online Textual Symptomatic Assessment Chatbot Based on Q&A Weighted Scoring for Female Breast Cancer Prescreening. Appl. Sci. 2021, 11(11), 5079.
Jenhui Chen, Obinna Agbodike, Wen-Ling Kuo, Lei Wang, Chiao-Hua Huang, Yu-Shian
Shen, Bing-Hong Chen
20. Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer. Diagnostics 2021, 11(8), 1460
Wen-Ling Kuo, Lin-Lu Tseng, Che-Chang Chang, Chih-Jung Chen, Mei-Ling Cheng, Hsin-Hung Cheng, Meng-Jen Wu, Yu-Lun Chen, Ruei-Ting Chang, Hsiang-Yu Tang, Yong-Chen Hsu, Wen-Jye Lin, Cheng-Yuan Kao, Wen-Ping Hsieh, Hsing-Jien Kung, Wen-Ching Wang
21. Robotic-Assisted Peripheral Nerve Surgery: A Systematic Review. J Reconstr Microsurg. 2021 Jul;37(6):503-513.
Lisa Wen-Yu Chen, Mei Goh, Raymond Goh, Yin-Kai Chao, Jung-Ju Huang, Wen-Ling Kuo Cheyenne Wei-Hsuan Sung, Johnny Chuieng-Yi Lu, David Chwei-Chin Chuang, Tommy Nai-Jen Chang
22. Discrepancy of Breast and Axillary Pathologic Complete Response and Outcomes in Different Subtypes of Node-positive Breast Cancer after Neoadjuvant Chemotherapy. J Cancer. 2021 Jul 6;12(17):5365-5374.
Shin-Cheh Chen, Chi-Chang Yu, Hsien-Kun Chang, Yung-Chang Lin, Yung-Feng Lo, Shih-Che Shen, Wen-Lin Kuo, Hsiu-Pei Tsai, Hsu-Huan Chou, Chia-Hui Chu, Wen-Chi Shen, Ren-Chin Wu, Shir-Hwa Ueng, Yi-Ting Huang
23. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment. BMC Surg. 2021 Mar 23;21(1):160.
Hsu-Huan Chou, Wei-Shan Chung, Rong-Yao Ding, Wen-Ling Kuo, Chi-Chang Yu, Hsiu-Pei Tsai, Shih-Che Shen, Chia-Hui Chu, Yung-Feng Lo, Shin-Cheh Chen
24. Retrospective Analysis of Clinicopathological Features and Familial Cancer History of Synchronous Bilateral Breast Cancer. Healthcare (Basel). 2021 Sep 13;9(9):1203.
Kai-Ling Huang, Yu-Ling Liu, Ya-Ying Hsu, Wen-Ling Kuo*
25. Direct-to-implant breast reconstruction following nipple-sparing mastectomy: predictive factors of adverse surgical outcomes in Asian patients. Arch Plast Surg. 2021 Sep;48(5):483-493.
Chun-Lin Su, Jia-Ruei Yang, Wen-Ling Kuo , Shin-Cheh Chen, David Chon-Fok Cheong, Jung-Ju Huang
26. Robotic-assisted Nipple-sparing Mastectomy Followed by Immediate Microsurgical Free Flap Reconstruction: Feasibility and Aesthetic Results – Case Series. International Journal of Surgery. 2021 Oct 16;106143 (SCI; IF = 15.3; Surgery 2/211)
Jung-Ju Huang, Eva Yu-Hsuan Chuang, David Chon-Fok Cheong, Bong-Sung Kim, Frank Chun-Shin Chang, Wen-Ling Kuo*
(SCI; IF = 15.3; Surgery 2/211)
27. Long-Term Outcomes of Breast Cancer Patients Who Underwent Selective Neck Dissection for Metachronous Isolated Supraclavicular Nodal Metastasis. Cancers (Basel). 2021 Dec 29;14(1):164. doi: 10.3390/cancers14010164.
Chen SC, Shen SC, Yu CC, Huang TS, Lo YF, Chang HK, Lin YC, Kuo WL, Tsai HP, Chou HH, Lee LY, Huang YT.
28. The allergy mediator histamine confers resistanceto immunotherapy in cancer patients via activationof the macrophage histamine receptor H1. Cancer Cell. 2022 Jan 10; 18;S1535-6108(21)00602-4.
Hongzhong Li, Yi Xiao, Qin Li, Jun Yao, Xiangliang Yuan, Yuan Zhang, Xuedong Yin, Yohei Saito, Huihui Fan, Ping Li, Wen-Ling Kuo, Angela Halpin, Don L Gibbons, Hideo Yagita, Zhongming Zhao, Da Pang, Guosheng Ren, Cassian Yee, J Jack Lee, Dihua Yu*
29. Transcutaneous medial fixation sutures for free flap inset after robot-assisted nipple-sparing mastectomy. Arch Plast Surg. 2022 Jan;49(1):29-33.
Kim BS, Kuo WL, Cheong DC, Lindenblatt N, Huang JJ.
30. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discovery, 2022 Jul 6;12(7):1742-1759, DOI: 10.1158/2159-8290.cd-21-0900
Xiangliang Yuan, Yimin Duan, Yi Xiao, Kai Sun, Yutao Qi, Yuan Zhang, Zamal Ahmed, Davide Moiani, Jun Yao, Hongzhong Li, Lin Zhang, Arseniy E. Yuzhalin, Ping Li, Chenyu Zhang, Akosua Badu-Nkansah, Yohei Saito, Xianghua Liu, Wen-Ling Kuo, Haoqiang Ying, Shao-Cong Sun, Jenny C. Chang, John A. Tainer, Dihua Yu*
31. Factors Associated with Axillary Lymph Node Status in Clinically Node-Negative Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Cancers (Basel). 2022 Sep 14;14(18):4451.
Chi-Chang Yu, Yun-Chung Cheung, Shir-Hwa Ueng, Yung-Chang Lin, Wen-Ling Kuo, Shih-Che Shen, Yung-Feng Lo, Shin-Cheh Chen
32. Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients. Breast Cancer Res Treat. 2022 Apr;192(3):629-637.
Po-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, King-Jen Chang, Ai-Chu Huang, Kuo-Chih Cheng, Karen Yang, Hui-Chen Wu, Tsu-Yi Chao, Yuan-Ching Chang, Peng-Chan Lin, Wen-Hung Kuo, Wen-Lin Kuo, Ching-Hung Lin, Huo-Mu Chen, Dah-Cherng Ye, Liang-Chih Liu , Chun-Yu Liu, Ming-Yang Wang, Chiao Lo, Yen-Shen Lu, Chiun-Sheng Huang
33. A case report of breast cancer in silicone-injected breasts diagnosed by an emerging technique of contrast-enhanced mammography-guided biopsy. Case Reports. 2022 Jul 22; 12: 884576.
Yun-Chung Cheung, Wen-Lin Kuo, Li-Yu Lee, Ya-Chun Tang
34. Patients' attitudes regarding genetic counseling before germline BRCA1/2 pathogenic variants testing in Taiwan: A single-country, multi-center, patient-reported outcome study. J Genet Couns. 2023;00:1–10.
Wen-Ling Kuo, Po-Han Lin, Meng-Ting Peng, Chia-Hui Chu, Chia-Wei Cho
35. The Effect of Negative Pressure on Wound Healing and Regeneration in Closed Incisions under High Tension: Evidence from Animal Studies and Clinical Experience. J. Clin. Med. 2023; 12(1):106. doi:10.3390/jcm12010106
Hsiao HY, Hsieh WC, Chang FCS, Liu JW, Kuo WL, Cheong DCF, Huang JJ*.
36. Surgical and patient-reported outcomes in an Asian female population with or without adjuvant radiotherapy after immediate free perforator flap breast reconstruction: A retrospective review. JPRAS Open. 2023 Dec; 38: 237–248.
Wei-Chuan Hsieh, Richard Tee, Yi-Ting Huang, Wen-Ling Kuo, Jung-Ju Huang*
37. Novel Port Placement in Robotic-assisted DIEP Flap Harvest Improves Visibility and Bilateral DIEP Access: Early Controlled Cohort Study. Plast Reconstr Surg. 2023 Oct 1;152(4):590e-595e. doi:10.1097/PRS.0000000000010470
Tsai CY, Kim BS, Kuo WL, Liu KH, Chang TNJ, Cheong DCF, Huang JJ*.
38. Small Flaps in Microsurgical Breast Reconstruction: Selection Between the PAP and Small DIEP Flaps and Associated Outcomes and Complications. Microsurgery-Case reports. 2023 Apr 10. doi: 10.1002/micr.31046. DOI:10.1002/mic.31046
Chan SY, Kuo WL, Cheong DCF, Chang FCS, Huang JJ*.
39. The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience. Breast Cancer. 2024 Mar;31(2):252-262.
Yi-Wen Hong, I-Ming Kuo*, Wen-Ling Kuo, Chi-Chang Yu, Shih-Che Shen, Hsiu-Pei Tsai, Chia-Hui Chu, Hui-Yu Ho, Yung-Feng Lo, Shin-Cheh Chen, Yung-Chang Lin, Chih-Ying Chien, and Hsu-Huan Chou*
40. Elongation of intercostal nerve cutaneous branches for breast and nipple neurotization during breast reconstruction after mastectomy for breast cancer: case–control study. British Journal of Surgery, 2024 Jan 31;111(2): znae005.
Tommy Nai-Jen Chang, Johnny Chuieng-Yi Lu, Cheyenne Wei-Hsuan Sung, Amina M Illias, David Chon-Fok Cheong, Shu-Wei Kao, Wen-Ling Kuo, Lukas Pindur, Lisa Wen-Yu Chen, Jennifer An-Jou Lin, David Chwei-Chin Chuang, Jung-Ju Huang*
41. Six steps for a successful aesthetic free flap reconstruction after minimally invasive mastectomy: a retrospective case-control study. Int J Surg. 2024 Feb 1;110(2):645-653.
Allen Wei-Jiat Wong, Wen-Ling Kuo, David Chon-Fok Cheong, Hsiu-Pei Tsai, Shu-Wei Kao, Chia-Fang Chen, Jung-Ju Huang*
42. Strategically shifting paradigms: the new era of DIEP flaps with minimally invasive mastectomy: a retrospective cross-sectional study. BMC Cancer. 2024 Aug 30;24(1):1072.
Tzu-En Lin, Allen Wei-Jiat Wong, David Chon-Fok Cheong, Wen-Ling Kuo, Hsiu-Pei Tsai, Jung-Ju Huang*
43. Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer. Clinical trial. Sci Rep. 2024 Oct 28;14(1):25690.
Wen-Chi Shen, Shin-Cheh Chen, Cheng-Hsu Wang, Chao-Ming Hung, Meng-Ting Peng, Chien-Ting Liu, Yueh-Shih Chang, Wen-Ling Kuo, Hsu-Huan Chou, Kun-Yun Yeh, Tsung-Han Wu, Chun-Feng Wu, Pei-Hung Chang, Yen-Min Huang, Chi-Chang Yu, Chun-Hui Lee, Kun-Ming Rau*
44. Comparative analysis of oncological and surgical outcomes of robotic versus conventional mastectomy for breast cancer. Eur J Surg Oncol. 2025 Jan 21;51(5):109622.
Kuo WL*, Huang JJ, Chu CH, Chang SC, Lin YJ, Chuang YH, Li YC, Cheong CF, Liu YL, Chen SC.
45. Technical Pearls for Breast Reconstruction in Low BMI Asian Women with the Profunda Artery Perforator Flap. Microsurgery. 2025 Jan;45(1):e70009.
Wong AW, Cheong DC, Kuo WL, Chen CF, Huang JJ.
46. Coherences of Cesarean Sectioning Scars and Other Abdominal Scars and Venous Augmentation Using SIEV in Free DIEP Flaps for Breast Reconstruction. Microsurgery. 2025 Feb;45(2): e70039.
Tinhofer IE, Tsai TY, Cheong DC, Lin TE, Kuo WL, Huang JJ.
47. ASO Visual Abstract: Long-Term Follow-Up of Surgical Outcomes and Oncological Results of Nipple-Sparing Mastectomy with Immediate Reconstruction Through a Single Axillary Incision with Different Approach Methods. Ann Surg Oncol. 2025 Mar;32(3):2116.
Gau RY, Chou HH, Tsai HP, Shen SC, Kuo WL, Chu CH, Ho HY, Huang JJ, Lin YC, Huang YT, Yu CC, Chen SC.
48. Long-Term Follow-Up of Surgical Outcomes and Oncological Results of Nipple-Sparing Mastectomy with Immediate Reconstruction Through a Single Axillary Incision with Different Approach Methods. Ann Surg Oncol. 2025 Mar;32(3):2092-2102.
Ruoh-Yun Gau, Hsu-Huan Chou, Hsiu-Pei Tsai, Shih-Che Shen, Wen-Ling Kuo, Chia-Hui Chu, Hui-Yu Ho, Jung-Ju Huang, Yung-Chang Lin, Yi-Ting Huang, Chi-Chang Yu, Shin-Cheh Chen
49. Breast neurotization along with breast reconstruction after nipple sparing mastectomy enhances quality of life and reduces denervation symptoms in patient-reported outcome: a prospective cohort study. Int J Surg. 2025 May 1;111(5):3235-3247. doi: 10.1097/JS9.0000000000002331.
Shiuan Shyu, Tommy Nai-Jen Chang, Johnny Chuieng-Yi Lu, Chia-Fang Chen, David Chon-Fok Cheong, Shu-Wei Kao, Wen-Ling Kuo, Jung-Ju Huang
50. Consensus Statement on Robotic Nipple Sparing Mastectomy Expert Panel. J Breast Cancer. 2025 Jun;28(3):180-192
Jai Min Ryu, Chi Wei Mok, Antonio Toesca, Hung-Wen Lai, Wen-Ling Kuo, Fiona Tsui-Fen Cheng, Seung Yong Song, Jeffrey Johnson, Hyukjai Shin, Hyung Seok Park
51. Oncoplastic Entirely Robot-Assisted Approach (OPERA) – Incorporating Robotic Surgery in Both Mastectomy and DIEP Flap Reconstruction. Plast Reconstr Surg. 2025 Oct 1;156(4):451e-460e doi: 10.1097/PRS.0000000000012157.
Wen-Ling Kuo, Allen Wei-Jiat Wong, Chun-Yi Tsai, Yi-Fu Chen, Tommy Nai-Jen Chang, David Chon-Fok Cheong, Jung-Ju Huang*
52. Clinical Scenarios Using Thoracodorsal and Lateral Thoracic Vessels Versus Internal Mammary Vessels in Bipedicled Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Comparative Study. J Reconstr Microsurg. 2025 Oct 28. doi: 10.1055/a-2717-4996. Online ahead of print.
Chia-Fang Chen, David Chon-Fok Cheong, Wen-Ling Kuo, Chi-Chang Yu, Hsu-Huan Chou, Shin-Cheh Chen, Jung-Ju Huang

Presentation(s):